SYRE Spyre Therapeutics, Inc. Insider Trading

CFO Scott Burrows sells 7,500 shares at $87.55–$88.37 under 10b5-1 plan; retains 98.0K shares and 352,357 options.

Scott L Burrows, CFO of Spyre Therapeutics, executed 2 separate sales totaling 7,500 shares for $658,039.50 on 2026-07-01 at blended average price $87.74, representing a 7.1% reduction of his non-derivative holdings. This transaction is governed by a 10b5-1 trading plan adopted on 2025-11-10, meaning it is scheduled and not discretionary. The company remains unprofitable with net income of $-69,005,000.00 and revenue of $0.00 in its latest quarter, establishing a fundamental context of financial distress. Burrows retains 97,994 non-derivative shares post-transaction and 352,357 stock options, indicating his economic interest in the company remains substantial despite the structured sale. The stock currently trades at $86.63, roughly 15.1% below its 52-week high of $102.06, and has appreciated 25.3% over 30 days and 82.1% over 90 days—factors that do not bear on the timing of a scheduled sale plan.

CMO Sheldon Sloan sold 8,334 shares ($730.9K) via scheduled 10b5-1 plan; retains 305,000 option shares.

Sheldon Sloan, Chief Medical Officer at Spyre Therapeutics, executed 2 separate sales totaling 8,334 shares for $730,895.56 (blended average $87.70 per share) on 2026-07-01 under a pre-arranged 10b5-1 trading plan adopted on 2025-06-20. The transaction is scheduled rather than discretionary. His non-derivative holdings declined to zero, though he retains 305,000 stock options. The stock is currently trading at $86.63, down 15.1% from its 52-week high of $102.06, yet up 25.3% over the prior 30 days and 82.1% over 90 days. Spyre remains pre-revenue with a $69.0M net loss in its latest quarter and unprofitability over the full fiscal year. His prior trades at SYRE show positive 30-day returns ranging from 0.8% to 15.5%, suggesting his recent sales have generally been followed by continued appreciation. The scheduled nature of this trade removes timing as a meaningful signal, but the combination of zero non-derivative holdings alongside significant remaining derivative leverage and the company's lack of profitability presents the key context for investor review.

CEO Cameron Turtle sold 15,000 shares for $1.3M via scheduled 10b5-1 plan; holds 582.5K shares post-sale

Cameron Turtle, CEO of Spyre Therapeutics, executed three separate sales on 2026-07-01 totaling 15,000 shares for $1,315,346.42 at a blended average price of $87.69 per share, reducing his holdings from 597.5K to 582.5K shares (-2.5%). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-06-20, meaning the sales were scheduled in advance rather than discretionary. The company is unprofitable with net income of $-69,005,000.00 over its most recent full fiscal year and $0.00 revenue in the latest quarter. The current stock price of $86.63 is -15.1% from the 52-week high of $102.06, though it has risen +25.3% over the past 30 days and +82.1% over the past 90 days. Investors should note that pre-arranged 10b5-1 sales reflect scheduling decisions made months prior to execution, not real-time market judgment; simultaneous with this CEO sale activity, his prior same-ticker sales executed in June showed 30-day returns of +24.5%, +26.1%, and +28.1%, indicating the stock has trended upward after recent insider dispositions at this company.

CFO Scott L Burrows sells 15,000 SYRE shares for $1,307,000.00 on 2026-06-25 at $87.13 blended average

Scott L Burrows, Chief Financial Officer of Spyre Therapeutics, sold 15,000 shares across 2 separate transactions totaling $1,307,000.00, reducing his non-derivative holdings from 112,994 shares to 97,994 shares (-13.3%). The sales occurred at a 52-week price point 13.9% below the all-time high of $102.06, while the stock is up 21.2% over the prior 30 days and +85.8% over 90 days. Notably, Burrows retains 359,857 shares in stock options, meaning his overall position remains substantial. His cross-ticker track record shows a 100% well-timed rate on 5 prior sells, but same-ticker measurements are limited: only 1 of 5 prior SYRE trades has a measurable 90-day outcome (a -1.9% return in 2024), with 3 recent June 2026 sales still showing no measurable 30- or 90-day results. The company remains unprofitable with net income of $-69,005,000.00 and zero revenue in the latest quarter.

Director Michael Thomas Henderson sold 20,000 shares of SYRE at $100.00 on 2026-06-22 under pre-arranged 10b5-1 plan; stock now at $97.05

Michael Thomas Henderson (Director) executed a scheduled sale of 20,000 shares (20.0K shares) at $100.00 on 2026-06-22 under a pre-arranged 10b5-1 trading plan adopted on 2026-02-06, reducing his holdings by -22.6% vs pre-transaction levels to 68.6K shares. The transaction occurred while the stock trades at $97.05, which is -4.9% from the 52-week high of $102.06 and reflects strong recent momentum (+31.1% over 30 days, +112.5% over 90 days). Spyre Therapeutics remains unprofitable with latest quarter revenue of $0.00 and full-year net income of $-69.0M, yet carries a market cap of $8.4B. Because this sale is scheduled under a 10b5-1 plan, it reflects predetermined timing rather than a discretionary decision, limiting its informational content as a directional signal about Henderson's current conviction in the stock.

Director Fairmount Funds sold 4.68M SYRE shares for $399.7M at $85.31; zero non-derivative holdings remain post-trade.

Fairmount Funds Management LLC sold 4,684,781 shares of Spyre Therapeutics at $85.31 on 2026-06-23, reducing its non-derivative stake to zero while preserving zero Series B Preferred shares in the related vehicle. The sale occurred as the stock was at -4.9% from its 52-week high of $102.06, having rallied +31.1% in the prior 30 days and +112.5% over 90 days. The company remains unprofitable with a net loss of -$69,005,000 in the latest period and zero revenue, making the director's removal of non-derivative equity exposure notable given recent momentum and the company's ongoing burn rate. Across the director's cross-ticker history, prior sells averaged -3.9% returns over 30 days post-trade and showed a 0.00% well-timed rate, indicating that past sales have not preceded further declines.

CMO Sheldon Sloan sells 8,333 shares of SYRE for $624,975 under pre-arranged 10b5-1 plan; retains 313,334 options

Sheldon Sloan, Chief Medical Officer, sold 8,333 shares at $75.00 on 2026-06-03 totaling $624,975.00, pursuant to a 10b5-1 trading plan adopted on 2025-06-20 (scheduled, not discretionary). The sale represents his non-derivative holdings; he retains 313,334 shares in stock options post-transaction. The company is unprofitable with net income of $-69,005,000.00 for the most recent full fiscal year and $0.00 revenue in the latest quarter. Across his same-ticker history at SYRE, Sloan's prior five sales on 2026-05-01 showed mixed near-term outcomes (30-day range: -0.3% to +5.7%; 90-day range: -6.2% to -0.5%), with the 90-day returns consistently negative. At current price of $73.52, the stock is -6.7% from the 52-week high of $78.80 but +6.4% over 30 days and +81.1% over 90 days.

CEO Cameron Turtle sells 15,000 SYRE shares for $1.1M via scheduled 10b5-1 plan on 2026-06-01

Cameron Turtle, Chief Executive Officer of Spyre Therapeutics, executed three separate sales totaling 15,000 shares for $1,056,486.02 on 2026-06-01 under a pre-arranged 10b5-1 trading plan adopted on 2025-06-20. This transaction is scheduled, not discretionary. The company generated $0.00 in revenue in its latest quarter and reported a net loss of $-69,005,000.00, with negative full-year net income. Turtle's prior trades at SYRE show mixed price action: the five prior sells from 2026-05-01 posted 90-day returns ranging from -6.8% to -0.6%, while his cross-ticker track record across 12 prior sells averaged a 90-day return of +22.9%. The stock currently trades at $73.52, which is -6.7% from its 52-week high of $78.80 and +6.4% over the past 30 days.

CFO Burrows sells 7,500 shares ($532.9K) at $69.75–$72.06 via scheduled 10b5-1 plan; retains 97,994 shares + 374,857 stock options.

Scott L Burrows, CFO of Spyre Therapeutics, executed 3 separate sales totaling 7,500 shares for $532,936.98 on 2026-06-01 under a pre-arranged 10b5-1 trading plan adopted 2025-11-10. This is a scheduled, non-discretionary transaction. Post-sale, Burrows retains 97,994 shares in non-derivative holdings plus 374,857 shares through stock options, maintaining a substantial position. The sales occurred when SYRE's stock was at $69.75–$72.06 per share, versus the current price of $73.52; the stock has appreciated 6.4% over the prior 30 days and 81.1% over 90 days. Burrows' prior two sales at SYRE (2026-05-01 and 2024-09-03) preceded mixed subsequent returns (30-day gains followed by 90-day losses). The company is unprofitable with $0 revenue and -$69.0M net income in the latest quarter, a fundamental context relevant to evaluating insider positioning.

Director Michael Thomas Henderson sells 80,000 shares for ~$5.95M as stock rallies sharply from 52-week lows.

Michael Thomas Henderson, a director at Spyre Therapeutics, disposed of a substantial portion of his holdings—80,000 shares totaling nearly $6M—in four tranches on the same day. This marks a significant shift in his insider activity: his prior Form 4 filings show 20 consecutive sales and no open-market purchases over the look-back period. The timing is notable given the stock's dramatic price trajectory—it has surged over 40% in the past month alone and more than doubled over three months from deeply depressed levels near its 52-week low. However, Henderson's selling pattern carries mixed track record implications: while his prior sales have shown a 35% win rate of being well-timed (where a 90-day decline would validate the sale), his overall 90-day returns after selling have been modestly positive, suggesting the stock often continued rising after his exits. Spyre remains unprofitable with no revenue, positioning any insider activity in a pre-commercial biotech context where cash management and equity decisions carry operational weight.